Innovation to Impact Grants

This program is designed to support the logical next steps of a positive, innovative, 'high risk/high reward' research grant, with the goal of working towards or achieving a significant impact on cancer.

Originally designed to continue the CCS funding pipeline between successful Innovation and Impact Grants, with the merger between the CCS and the Canadian Breast Cancer Foundation (CBCF), eligibility for Innovation to Impact Grants has been expanded for this competition only. Applicants are cautioned to carefully review the full description for details on the eligibility criteria for this funding opportunity.

Scientific focus of the program and eligibility

Innovation to Impact Grants (i2I) are intended to support the further development of significant findings based on the goals originally explored through a funded CCS Innovation Grant or an eligible CBCF grant. Note: Only investigators with a funded Innovation Grant OR CBCF grant with a project end date between January 1, 2015 and July 31, 2018 are eligible for this program.

Applicants are required to articulate significant achievements from the original Innovation Grant or CBCF Grant (i.e., significant new knowledge, publications, intellectual property, technology development, or relevant endpoints) and clearly describe and justify the progression to the new research proposed. Applicants must also describe the potential for impact of the proposed project on cancer. Any applications that are not appropriate, as determined through a review of the abstract registration, will not be eligible to proceed to the full application stage.

Investigators looking to explore unexpected outcomes or ideas not originally proposed in a funded Innovation Grant or CBCF grant are encouraged to apply for a new Innovation Grant as the Innovation to Impact Grant program is designed to build upon successful outcomes from the objectives of the original Innovation/CBCF grant.

Please see the eligibility and requirements section prior to creating an application.

Deadline dates

Abstract registration due date: December 15, 2017
Relevance review results: early February, 2018
Full application due date: March 29, 2018
Results announcement: mid-late July
Anticipated start date: August 1, 2018

Application guides can be found on the EGrAMS documentation for applicants page. See FAQs.

Abstract registration must be completed in order to submit a full application. An eligibility review will be conducted and only successful applicants will be invited to submit a Full Application.

Funds available

It is expected that up to 11 grants will be awarded in this competition.

Given the merger of the Canadian Breast Cancer Foundation (CBCF) with CCS, a special call for breast cancer research is included in this competition. For applicants wishing to be considered under the breast cancer call, a relevance statement is required that explicitly demonstrates how the project is relevant to breast cancer.

Grant budgets may be up to $150,000 per year with a maximum of 3 years of funding. Grants will be non-renewable.

Funding will be provided to support the direct costs of research, including supplies, salaries, and equipment associated with the proposed work. Equipment requests should not exceed $50,000 of the requested budget however an increase in this portion of the budget will be considered as an exceptional case if the i2I application involves the development of a technology or a platform that requires specific equipment to do so.  Indirect costs are not eligible.

Peer review panels

Peer review committees will consist of scientific members with expertise relevant to the disciplines of research under review, as well as community representatives. External reviewers may also be recruited.

Review panel information can be found here.

Abstract registration

A maximum of one i2I grant application resulting from a single Innovation or CBCF Grant is allowed and must be submitted by the Principal Investigator or Co-Principal Investigator of the original Innovation Grant.

Registration is mandatory and will require applicant details (Principal Investigator(s)/Co-applicants/Additional Authors), scientific abstract, keywords and research tracking information, a statement of the achievements resulting from the Innovation or CBCF Grant, as well as the potential for impact of the proposed grant. There is no limit on the number of re-applications, however, applications may only be made for Grants with an end date between January 1, 2015 and July 31, 2018.

Application structure

When preparing the full application, the following will be required:

  1. as part of the public (non-scientific) summary, a cancer relevance statement describing the potential of this project to impact cancer control
  2. a scientific abstract
  3. a demonstration of significant achievements from the stated goals in the funded Innovation/CBCF Grant and discussion of the clear progression of the work outlined in the i2I proposal (no more than 2 pages of single spaced text). Progress must be a direct result of the work completed within the Innovation/CBCF Grant. Note that a publication resulting from the original Innovation grant is not required but it is necessary to include a clear description of specific outcomes and include relevant preliminary data in the i2I proposal.
  4. a detailed scientific proposal clearly stating the aims of the project including any previous work done in the area, study design, methods and analysis; a description of the expected impact that research results will have on reducing the burden of cancer; details of the investigator(s) including which member(s) of the research team will be responsible for which aspect of the project and a rationale for their inclusion in the project, as well as a description of the research environment where the work will take place (no more than 6 pages of single spaced text) 
  5. a vision statement explicitly describing how the proposed work could move the field forward and accelerate progress in cancer research.
  6. data figures/tables/charts and their associated legends (no more than 5 pages)
  7. submission of the original Innovation/CBCF Grant proposal and scientific abstract, as well as the innovation statement (for Innovation Grants only).
  8. a budget justification related to the supplies, equipment and personnel associated with the research project. This must include the number of personnel required to complete the work and a description of their experience and/or education level and their commitment to the project. The budget request must be appropriate for the type of research proposed.

Specific guidelines for the online application will be available shortly after the relevance review is complete.

Review criteria

The eligibility review will be conducted after the abstract registration phase and will be based on:

  • demonstration of significant achievements/productivity in the original Innovation/CBCF grant
  • logical progression of work from the original grant to the current application, building on achievements from the original Innovation/CBCF grant
  • potential of the current proposal for impact on cancer

The review criteria for the full application will include the following:

  • evidence of the successful testing of the hypotheses from the original Innovation/CBCF Grant
  • evidence of significant achievements made in the original Innovation/CBCF Grant
  • evidence of progression to show how the proposed work builds upon significant findings from the original Innovation/CBCF Grant
  • potential for impact
  • feasibility and scientific merit 
  • qualifications and experience of the investigator(s) 
  • quality of the research environment
  • potential for the advancement of the mission of the Canadian Cancer Society
  • appropriateness of the term and amount of support requested

Multiple applications/multiple sources of funding

There must not be substantial overlap (i.e. more than 50%) with any pending application (including those at the registration, abstract or Letter of Intent submission stage) to any other CCS research program as of this competition due date. Duplicate applications will not be accepted. The onus is on the applicant to indicate the extent (or absence) of overlap. Grantees can accept funds from other sources, up to the CCS research panel recommended amount in cases where the panel approved amount exceeds the annual funding limit.

Applicants are reminded to review the eligibility and requirements section for details on scientific and financial reporting, funder acknowledgement, Canadian Cancer Society policies on open access and tobacco related funding. 

Last modified on: November 3, 2017